ctDNA assay
tumour, CRC
TUMOUR
In collaboration with Guardant Health, we will use the Guardant Reveal ctDNA assay to analyse blood samples. The Guardant Reveal assay is the first and only blood-based tumour-naïve ctDNA assay to detect MRD in early CRC. It leverages several technical advances in ctDNA detection to improve assay sensitivity without requiring a priori knowledge of the tumour genotype. The technique combines genomic and methylation features with independent analyses occurring in parallel to increase sensitivity. It has a turnaround time of 7–14 days for results processed in real time for clinical use. It is Clinical Laboratory Improvement Amendments (CLIA) certified and was approved by the Food and Drug Administration (FDA) in March 2021, and is already in use in three global interventional clinical trials [